Clinical trials: HIV-1
HIV Infections
Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
This study will evaluate the safety and efficacy of the human monoclonal antibody (mAb) VRC-HIVMAB060-00-AB (VRC01) in preventing HIV-1 infection among men and transgender (TG) persons who have sex with men, in North America…
- Trial name
- NCT02716675
- Testing
- VRC01
- Where
- 26 sites in United States, Brazil and 2 more
- Volunteers
- 2,699 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants
This FTIH study aims to evaluate the safety, tolerability and PK of the novel investigational Human immunodeficiency virus (HIV)-1 capsid inhibitor VH4011499 in healthy adults.
- Trial name
- NCT05393271
- Testing
- VH4011499, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus Infections
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
The purpose of this study was to compare the safety, tolerability, and antiviral activity of once-daily (QD) and twice-daily (BID) dosing of the lopinavir/ritonavir (LPV/r) tablet formulation in combination with…
- Trial name
- NCT00358917
- Testing
- lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
- Where
- United States
- Volunteers
- 599 people
- Sponsor
- Abbott
HIV-1
A Phase 2B Multicenter, Randomized, Comparative Trial Of UK-453,061 Versus Etravirine In Combination With Darunavir/Ritonavir And A Nucleos(t)Ide Reverse Transcriptase Inhibitor For The Treatment Of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence Of NNRTI Resistant HIV-1
This is a 96 week study to determine if UK- 453,061 in combination with Darunavir /ritonavir and a Nucleos(t)ide Reverse Transcriptase inhibitor is as efficacious, safe and tolerable as etravirine in combination with Darunavir…
- Trial name
- NCT00823979
- Testing
- UK-453,061 Dose 1, UK-453,061 Dose 2, Etravirine
- Where
- 63 sites in United States, Brazil and 11 more
- Volunteers
- 105 people
- Sponsor
- Pfizer
HIV Infections, Hepatitis C
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
Infection with both HIV and hepatitis C virus (HCV) may result in serious and sometimes fatal liver disease. The purpose of this study was to test the effectiveness of long-term pegylated interferon alfa-2a (PEG-IFN) and…
- Conditions
- HIV Infections, Hepatitis C, Liver Disease
- Trial name
- NCT00078403
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 37 sites in United States, Puerto Rico
- Volunteers
- 333 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Human Immunodeficiency Virus
MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
This is a single-dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and anti-retroviral activity of MK-8527 in antiretroviral therapy (ART)-naïve participants living with human immunodeficiency virus type…
- Trial name
- NCT05494736
- Testing
- MK-8527
- Where
- 4 sites in Romania, South Africa
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
The primary objective of this study is to evaluate the noninferiority of switching to emtricitabine/rilpivirine /tenofovir alafenamide (FTC/RPV/TAF) fixed-dose combination (FDC) as compared to continuing FTC/RPV/tenofovir…
- Trial name
- NCT02345252
- Testing
- FTC/RPV/TAF, FTC/RPV/TDF
- Where
- 117 sites in United States, Belgium and 10 more
- Volunteers
- 632 people
- Sponsor
- Gilead Sciences
Human Immunodeficiency Virus-1
A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients
This is a pilot study to examine if the novel treatment regimen maraviroc plus boosted atazanavir can be expected to be safe and efficacious in treatment naive HIV infected patients.
- Trial name
- NCT00827112
- Testing
- maraviroc
- Where
- 39 sites in United States, Germany and 1 more
- Volunteers
- 129 people
- Sponsor
- ViiV Healthcare
Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human
A Study of MGD020 Alone or Combined With MGD014 in Persons With HIV-1 on Antiretroviral Therapy
Study CP-MGD020-01 is a phase 1, open-label, dose-escalation, and multi-dose expansion study of MGD020 as a single agent or in combination with MGD014 in persons with HIV-1 (PWH) on antiretroviral therapy (ART).
- Conditions
- Human Immunodeficiency Virus I Infection, Immunodeficiency Virus Type 1, Human, Human Immunodeficiency Virus Type 1
- Trial name
- NCT05261191
- Testing
- MGD020, MGD014
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- MacroGenics
HIV Infections, Hepatic Impairment
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
The purpose of the study was to assess the steady-state pharmacokinetics (PK) of efavirenz (EFV) in human immunodeficiency virus type 1 (HIV-1) infected subjects on stable antiretroviral regimens containing EFV, and having…
- Trial name
- NCT00162097
- Testing
- efavirenz containing antiretroviral regimen
- Where
- 4 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Bristol-Myers Squibb
Human Immunodeficiency Virus (HIV)
Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)
The purpose of this study is to compare the antiretroviral activity of doravirine, tenofovir, lamivudine (MK-1439A), a single-tablet, once-daily (q.d.) fixed-dose combination (FDC) containing doravirine (MK-1439A) 100 mg +…
- Trial name
- DRIVE-AHEAD (NCT02403674)
- Testing
- Doravirine, Tenofovir, Lamivudine, ATRIPLA™
- Volunteers
- 734 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response
A research study to measure the effect on CD4 counts of adding to current anti-retroviral regimen raltegravir with or without hyper-immune bovine colostrum.
- Trial name
- CORAL (NCT00772590)
- Testing
- Raltegravir, Hyper-immune Bovine Colostrum, raltegravir and hyper-immune bovine colostrum
- Volunteers
- 75 people
- Sponsor
- Kirby Institute
HIV-1 Infection
Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate
This study is being done with people with HIV infection who have low levels of HDL-C. HDL-C is a type of "good" cholesterol. People with low HDL-C have a higher risk of heart disease and may have problems with how their blood…
- Trial name
- NCT01426438
- Testing
- Niacin, Aspirin, Fenofibrate
- Where
- 14 sites in United States
- Volunteers
- 99 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Infections
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease…
- Trial name
- NCT00976950
- Testing
- Tipranavir, ritonavir
- Where
- 20 sites in Romania
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
ART Adherence, HIV-1-infection
Call for Life Youth ART Adherence Study
Study purpose: To assess effect of mHealth Call for life Uganda tool (CFLU) on ART adherence among youth measured by interactive voice response to daily adherence calls mapped in the database and proportion with viral suppression…
- Conditions
- ART Adherence, HIV-1-infection, mHealth
- Trial name
- C4L-Youth (NCT04718974)
- Testing
- mHealth call for life system/ tool using IVR ( interactive voice response)
- Where
- Uganda
- Volunteers
- 206 people
- Sponsor
- Makerere University